NASDAQ:CODX - Nasdaq - US1897631057 - Common Stock - Currency: USD
0.61
-0.09 (-13.48%)
The current stock price of CODX is 0.61 USD. In the past month the price decreased by -24.03%. In the past year, price decreased by -47.34%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.9 | 234.07B | ||
ISRG | INTUITIVE SURGICAL INC | 80.63 | 210.79B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.59 | 153.85B | ||
SYK | STRYKER CORP | 31.82 | 147.88B | ||
MDT | MEDTRONIC PLC | 16.89 | 115.62B | ||
BDX | BECTON DICKINSON AND CO | 16.56 | 66.13B | ||
EW | EDWARDS LIFESCIENCES CORP | 27.77 | 42.91B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.17 | 41.38B | ||
IDXX | IDEXX LABORATORIES INC | 41.21 | 37.96B | ||
DXCM | DEXCOM INC | 55 | 35.45B | ||
RMD | RESMED INC | 25.98 | 33.73B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.79 | 24.42B |
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company is headquartered in Salt Lake City, Utah and currently employs 155 full-time employees. The company went IPO on 2017-07-12. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The firm also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. The company is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
CO-DIAGNOSTICS INC
4049 S Highland Dr
Salt Lake City UTAH 84109 US
CEO: Dwight Egan
Employees: 155
Company Website: http://codiagnostics.com/
Investor Relations: https://ir.codiagnostics.com/
Phone: 18012789769
The current stock price of CODX is 0.61 USD. The price decreased by -13.48% in the last trading session.
The exchange symbol of CO-DIAGNOSTICS INC is CODX and it is listed on the Nasdaq exchange.
CODX stock is listed on the Nasdaq exchange.
6 analysts have analysed CODX and the average price target is 1.53 USD. This implies a price increase of 150.82% is expected in the next year compared to the current price of 0.61. Check the CO-DIAGNOSTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CO-DIAGNOSTICS INC (CODX) has a market capitalization of 19.48M USD. This makes CODX a Nano Cap stock.
CO-DIAGNOSTICS INC (CODX) currently has 155 employees.
CO-DIAGNOSTICS INC (CODX) has a resistance level at 0.74. Check the full technical report for a detailed analysis of CODX support and resistance levels.
The Revenue of CO-DIAGNOSTICS INC (CODX) is expected to decline by -39.83% in the next year. Check the estimates tab for more information on the CODX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CODX does not pay a dividend.
CO-DIAGNOSTICS INC (CODX) will report earnings on 2025-03-12, after the market close.
CO-DIAGNOSTICS INC (CODX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.27).
The outstanding short interest for CO-DIAGNOSTICS INC (CODX) is 0.84% of its float. Check the ownership tab for more information on the CODX short interest.
ChartMill assigns a fundamental rating of 3 / 10 to CODX. While CODX has a great health rating, there are worries on its profitability.
Over the last trailing twelve months CODX reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS increased by 8.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -57.04% | ||
ROE | -64.73% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 43% to CODX. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -2.84% and a revenue growth -39.83% for CODX